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M I C R O B I O L O G Y
The Rab32/BLOC-3–dependent pathway mediates host 
defense against different pathogens in human 
macrophages
Massimiliano Baldassarre1*†, Virtu Solano-Collado1*, Arda Balci1, Rosa A. Colamarino1,  
Ivy M. Dambuza1,2, Delyth M. Reid1, Heather M. Wilson1, Gordon D. Brown1,2, 
Subhankar Mukhopadhyay3, Gordon Dougan4, Stefania Spanò1‡
Macrophages provide a first line of defense against microorganisms, and while some mechanisms to kill patho-
gens such as the oxidative burst are well described, others are still undefined or unknown. Here, we report that 
the Rab32 guanosine triphosphatase and its guanine nucleotide exchange factor BLOC-3 (biogenesis of lysosome- 
related organelles complex–3) are central components of a trafficking pathway that controls both bacterial and 
fungal intracellular pathogens. This host-defense mechanism is active in both human and murine macrophages 
and is independent of well-known antimicrobial mechanisms such as the NADPH (reduced form of nicotinamide 
adenine dinucleotide phosphate)–dependent oxidative burst, production of nitric oxide, and antimicrobial pep-
tides. To survive in human macrophages, Salmonella Typhi actively counteracts the Rab32/BLOC-3 pathway through 
its Salmonella pathogenicity island-1–encoded type III secretion system. These findings demonstrate that the 
Rab32/BLOC-3 pathway is a novel and universal host-defense pathway and protects mammalian species from 
various pathogens.
INTRODUCTION
Cells of our innate immune system, e.g., macrophages, are involved 
in the first line of defense against microorganisms. After phagocy-
tosis, macrophages can eliminate most of the microorganisms they 
encounter by directing them in intracellular compartments where 
conditions are not compatible with microorganism life. A key strat-
egy used by macrophages to kill microbes is the production of re-
active oxygen species (ROS) through activation of the NADPH 
oxidase complex that is assembled on cellular membranes in re-
sponse to infection (1). Other mechanisms, such as the production 
of nitric oxide, or cathelicidin-related antimicrobial peptide (Cramp), 
can also mediate bacterial killing (2). Despite the presence of a num-
ber of potent antimicrobial mechanisms, some microorganisms have 
evolved to become effective intracellular pathogens by escaping 
clearance and killing mechanisms present in macrophages and oth-
er immune cell types. For example, Salmonella enterica harbors two 
type III secretion systems that are responsible for the delivery of a 
battery of effectors that allow Salmonella to actively invade host 
cells, including macrophages, and survive in a specialized intracel-
lular compartment known as the Salmonella-containing vacuole 
(SCV) (3–5). S. enterica is a genetically diverse bacterial species that 
includes hundreds of different serovars that can cause human and 
important veterinary diseases. S. enterica serovar Typhi (S. Typhi) is 
a human-restricted serovar that causes typhoid fever, a disease that 
affects ≈22 million people every year (6). Unlike many Salmonella 
serovars that can infect a broad range of hosts, S. Typhi naturally 
only infects humans (7). For example, it cannot establish an oral in-
fection in laboratory mice (8).
Previously, we have shown that the inability of S. Typhi to infect 
mice depends, at least in part, on the fact that this pathogen cannot 
target the Rab32 GTPase in mouse macrophages (9). This GTPase 
and its guanine nucleotide exchange factor BLOC-3 (biogenesis of 
lysosome-related organelles complex–3) are central components of a 
pathway that regulate membrane trafficking to lysosome-related 
organelles in several specialized cell types (8, 9). The murine Rab32/
BLOC-3 pathway is effectively neutralized by the murine-virulent 
S. enterica serovar Typhimurium (S. Typhimurium) through the 
delivery of two Salmonella Pathogenicity Island 2 (SPI-2) type III 
secretion effectors, GtgE and SopD2, that directly target Rab32 by 
acting as a protease and a GTPase- activating protein, respectively 
(8, 10). S. Typhimurium mutants defective for both these effectors 
are virtually avirulent in wild-type mice but are able to infect mice 
that are either deficient for Rab32 or BLOC-3 (10).
RESULTS
Our previous work suggested that the Rab32/BLOC-3–dependent 
pathway limits the infectivity of bacteria that have not evolved to 
neutralize it. Therefore, we investigated whether this pathway can 
control other pathogens that are known to persist intracellularly. 
When bone marrow–derived macrophages (BMDMs) from wild-type, 
Rab32, or BLOC-3–deficient mice were infected with Staphylococcus 
aureus, we observed a substantial increase in intracellular persistence 
in BMDMs deficient for the Hermansky-Pudlak Syndrome 4 (HPS4) 
protein, one of the two subunits of BLOC-3, or Rab32 when com-
pared to wild-type BMDMs (Fig. 1A and fig. S1). In line with this, 
Rab32 is recruited to the vacuole containing S. aureus in wild-type 
but not HPS4-deficient BMDMs (Fig. 1B). Given that S. aureus is a 
Gram-positive bacterium, these data suggested that Rab32 and 
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BLOC-3 are components of an antimicrobial pathway that is im-
portant for the clearance of a number of different bacterial patho-
gens. Therefore, we investigated whether this pathway can also limit 
infection by fungal pathogens. Wild-type and HPS4-deficient mice 
were infected with Candida albicans, and the fungal burden in kid-
neys, the main organ affected by this pathogen, was evaluated 72 
hours post-infection (p.i.). BLOC-3–deficient mice exhibited a 
14-fold increase in kidney fungal colony-forming units (CFUs) (Fig. 1C). 
These results indicate that the Rab32/BLOC-3–dependent pathway 
is critical for defending the host from both bacterial and fungal attacks.
To investigate potential mechanisms for the Rab32-dependent 
clearance, we infected BMDMs from wild type and mice defective 
in particular antimicrobial factors with S. Typhi. ROS are molecules 
that are toxic to many species that have not evolved strategies to 
neutralize them (11). Innate immune cells can assemble phagocytic 
NADPH oxidase on the phagosome to generate ROS to kill intra-
cellular pathogens (12). BMDMs derived from NADPH oxidase- 
deficient mice (Phox−/−) clear S. Typhi similarly to wild-type BMDM, 
while an S. Typhi strain engineered to deliver the protease GtgE that 
cleaves Rab32 (8) is not killed so efficiently in either macrophage 
(Fig. 2A). Similarly, the production of nitric oxide radicals by the 
inducible nitric oxide synthase (iNOS) and Cramp, two important 
mechanisms that control pathogenic species, is not essential to clear 
S. Typhi in murine BMDMs (Fig. 2, B and C). These data indicate 
that the Rab32/BLOC-3–dependent pathway works independently 
of these well-characterized mechanisms of pathogen clearance and 
that another unknown mechanism underpins that ability of the 
Rab32 pathway to clear S. Typhi infections in murine cells.
The broad-host Salmonella serovar S. Typhimurium delivers 
two type III secretion effectors GtgE and SopD2 that confer the abil-
ity of isolates of this serovar to infect mice (8, 9, 13). S. Typhi lacks 
these two effectors and cannot infect mice but is able to survive in 
human macrophages and cause a systemic infection in humans. 
These facts could suggest that the Rab32/BLOC-3–dependent host- 
defense pathway is not fully active in human macrophages. However, 
the Rab32 and BLOC-3 genes are present in humans and genome- 
wide association studies have shown that single-nucleotide poly-
morphisms in the Rab32 untranslated regions are associated with 
increased susceptibility to leprosy, a human bacterial infection caused 
by the intracellular bacterium Mycobacterium leprae (14, 15). This 
suggests that Rab32 could be part of a pathway critical to control 
some bacterial infection in humans. Two scenarios could explain 
these findings: (i) Rab32/BLOC-3 are not part of a host-defense 
pathway in humans or (ii) a Rab32/BLOC-3–dependent pathway is 
active in humans as an antimicrobial mechanism, but S. Typhi has 
evolved molecular strategies to evade it.
To assess whether the Rab32/BLOC-3 host-defense pathway is 
active as an antimicrobial pathway in humans, we investigated the 
requirement of Rab32 and BLOC-3 in controlling bacterial growth 
in human macrophages. We used an S. Typhi strain engineered to 
express the S. Typhimurium type III secretion effector GtgE, a spe-
cific protease that cleaves the three Rab GTPases, Rab32, Rab29, 
and Rab38 (8, 16). We infected human macrophage-like THP-1 cells 
with an S. Typhi wild-type isolate [ISP2825 (17)] or an isogenic strain 
engineered to express GtgE (S. Typhi::gtgE). GtgE delivery from 
S. Typhi results in the cleavage of human Rab32 (Fig. 3A), indicat-
ing that GtgE can target endogenous human Rab32, in agreement 
with the previous observation that GtgE cleaves ectopically expressed 
human Rab32 (8). When we infected human blood monocyte– 
derived primary macrophages, we observed that Rab32 localizes on 
the surface of the vacuoles containing wild-type S. Typhi but is most-
ly absent from the surface of the vacuoles containing S. Typhi::gtgE 
(Fig. 3, B and C).
We then investigated whether the removal of Rab32 from the 
bacterial vacuole has any effect on S. Typhi survival. GtgE expres-
sion confers S. Typhi a threefold replicative advantage in blood 
monocyte–derived primary macrophages at 24 hours p.i. (Fig. 4A), 
suggesting that one of the three Rab GTPases targeted by GtgE 
(8, 16) controls S. Typhi intracellular survival in human macrophages. 
As Rab38 mRNA is hardly detectable in either THP-1 or primary 
macrophages (fig. S2 and “The Human Protein Atlas”), we analyzed 
whether either Rab32 or Rab29 is responsible for the limitation of 
S. Typhi growth in human macrophages by knocking down either 
Rab29 or Rab32 from THP-1 cells (>70 and >80% knockdown, re-
spectively; fig. S2). While depletion of Rab32 resulted in a sig-
nificantly increased replication of S. Typhi (Fig. 4B), only a slightly 
reduced replication was observed when Rab29 was depleted. Together, 
these results indicate that Rab32 is critical to control S. Typhi infec-
tions in human macrophages.
We then used macrophages derived from human-inducible plu-
ripotent stem cells (hiPSCs), a recently established model for the 
study of Salmonella infection (18, 19). First, we confirmed that, sim-
ilarly to what was observed in THP-1 and primary macrophages, 
GtgE expression also confers an advantage to S. Typhi in hiPSC- 
derived macrophages (Fig. 4C). Next, we used CRISPR-Cas9 tech-
nology to generate hiPSCs deficient for HPS4. As shown in Fig. 4D, 
Fig. 1. The Rab32/BLOC-3–dependent pathway mediates the killing of different pathogens. (A and B) BMDMs were derived from control mice C57BL/6 (wt) or from 
HPS4−/− mice, infected with S. aureus and (A) CFUs were enumerated at the times indicated or (B) cells were fixed at 3 hours post-infection (p.i.) and stained to show Rab32 
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macrophages derived from two independent clones of HPS4- 
deficient hiPSCs have a significant increased number of S. Typhi 
intracellular CFUs at 24 hours p.i., demonstrating that BLOC-3 is 
important to limit S. Typhi growth in human macrophages. To ob-
tain further insights into the effects of GtgE expression in S. Typhi 
or the knockout of BLOC-3 in these macrophages, we measured the 
number of S. Typhi in single cells by immunofluorescence (Fig. 4E) 
or flow cytometry analysis (Fig. 4F). These experiments confirmed 
that removal of either Rab32, obtained through GtgE delivery, or 
BLOC-3 results in an increased percentage of host cells containing 
higher numbers of bacteria. This indicates that both Rab32 and its 
guanine nucleotide exchange factor BLOC-3 are required for the 
control of Salmonella survival and replication in human macrophages. 
We also observed that although S. Typhi has a replicative advantage 
in the absence of BLOC-3, the expression of GtgE does not confer 
any significant additional advantage (Fig. 4C), in agreement with 
the model that Rab32 and BLOC-3 are components of the same 
pathway. The results of these experiments indicate that the Rab32/
BLOC-3–dependent pathway is active as a host-defense pathway in 
human macrophages and can limit S. Typhi replication.
To test whether the human Rab32/BLOC-3–dependent pathway 
exerts broad antimicrobial activity, we infected macrophages derived 
from two independent clones of HPS4-deficient hiPSCs with S. aureus. 
As shown in Fig. 5A, HPS4 knockout results in ≈10-fold increased 
survival of S. aureus in human macrophages. However, in contrast 
to S. aureus (Fig. 5A) and other pathogens, such as Escherichia coli 
O157 (Fig. 5B), S. Typhi is not as efficiently cleared by wild-type 
human macrophages during infection but instead persist in the ma-
jority of infected cells (Figs. 5B and 4, A to D). Therefore, we hypoth-
esized that S. Typhi actively counteracts the pathway controlled by 
Rab32/BLOC-3. Because the broad-host S. Typhimurium neutralizes 
this pathway through the action of effectors delivered by type III 
secretion systems, we tested whether S. Typhi survival in wild-type 
human macrophages is dependent on S. Typhi type III secretion 
systems. We observed that S. Typhi survival in hiPSC macrophages 
is dependent on its SPI-1 (Fig. 5C), but not on its SPI-2 type III se-
cretion system (fig. S3). An SPI-1 type III secretion system mutant 
of S. Typhi (S. Typhi∆invA) was unable to survive in macrophages 
derived from hiPSCs (Fig. 5C), in agreement with published results 
(20). S. Typhi∆invA survived much better in HPS4-deficient mac-
rophages (Fig. 5C), suggesting that the Rab32/BLOC-3 pathway is 
involved in S. Typhi killing and that S. Typhi needs this secretion 
system to counteract this pathway. To confirm that HPS4 removal 
did not result in a completely impaired bacterial killing, we infected 
HPS4-deficient macrophages with pathogenic E. coli O157. This 
pathogen is not able to survive in either wild-type or HPS4-deficient 
macrophages (Fig. 5D). These results indicate that S. Typhi is able 
to target the human Rab32/BLOC-3–dependent pathway likely 
through expression of the SPI-1 type III secretion system. As S. Typhi 
cannot neutralize the mouse Rab32/BLOC-3–dependent pathway, 
we suggest that S. Typhi targets a human-specific component of this 
pathway.
DISCUSSION
Overall, we show that Rab32 and BLOC-3 regulate host-defense 
activity against a variety of pathogens, including Gram-negative 
Fig. 3. GtgE delivery from S. Typhi results in the cleavage of human Rab32. 
(A) PMA-differentiated THP-1 cells were left uninfected or infected with either 
wild-type S. Typhi (WT) or an S. Typhi strain expressing GtgE (::gtgE). Cells were lysed 
2.5 hours p.i. and analyzed by Western blot with a Rab32-specific antibody. (B and 
C) Peripheral blood monocyte–derived macrophages were infected with either 
wild-type S. Typhi (WT) or an S. Typhi derivative expressing GtgE (::gtgE), both car-
rying a chromosomal copy of the mCherry gene, fixed at 2.5 hours p.i. and analyzed 






Fig. 2. The Rab32/BLOC-3–dependent pathway does not require oxidative burst to clear bacterial and fungal infections in murine cells. BMDMs were infected with 
S. Typhi wild-type (WT) or expressing GtgE (::gtgE), and CFUs were enumerated at the times indicated. (A) BMDMs were derived from control mice (wt) or from NADPH 
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and Gram-positive bacterial pathogens and the fungal pathogen 
C. albicans. This activity is critical for the clearance of S. aureus and 
S. Typhi in mouse macrophages and for the clearance of S. aureus in 
human macrophages but is dispensable for E. coli killing. While nei-
ther the overall antimicrobial mechanism nor mechanisms con-
trolled by Rab32 are yet defined, we show here that they do not 
require the production of ROS by the phagocytic NADPH oxidase, 
an ancient and broad antimicrobial mechanism active in macro-
phages. We also demonstrate that this activity does not require pro-
duction of nitric oxide by iNOS and the macrophage antimicrobial 
peptide CRAMP.
In agreement with previous studies (21), we found that removal 
of Rab32 induces a general decrease in lysosome acidification in hu-
man macrophages (fig. S4). However, considering that Salmonella is 
resistant to the low phagosome pH in macrophages (22), it is not 
clear how this decrease in acidification can result in a substantial 
increase in intracellular persistence. It is also possible that Rab32 and 
BLOC-3 control different antimicrobial mechanisms; however, while 
this paper was under revision, a new study by Chen et al. (23) has 
shown that Rab32 is important for the delivery of itaconic acid to 
the SCV resulting in bacterial killing.
In contrast to S. aureus, S. Typhi uses its SPI-1 type III secretion 
system to evade this pathway in humans and persist in human mac-
rophages. Not dissimilar from S. Typhimurium, which has evolved 
to deliver the protease GtgE and the Rab GAP SopD2 that act re-
dundantly to inactivate the murine Rab32/BLOC-3 trafficking 
pathway, S. Typhi appears to have evolved a strategy to target the 
human Rab32/BLOC-3–dependent pathway that requires its SPI-1 
type III secretion system. A possible reason for evolving a different 
strategy could rely on the fact that GtgE also targets Rab29, which is 
required for the efficient delivery of typhoid toxin from S. Typhi–
infected cells (16). Therefore, we speculate that GtgE, although able 
to cleave the human Rab32, would not confer, overall, an advantage 
to S. Typhi because it would interfere with other pathogenic fea-
tures of this bacterium, including the delivery of typhoid toxin. 
Similar to S. Typhimurium, S. Typhi may have evolved a number of 
A B C
P < 0.05




















Fig. 4. Rab32 inactivation and BLOC-3 knockout results in S. Typhi over-replication in human macrophages. (A) Peripheral blood monocyte–derived macrophages 
were infected with either wild-type S. Typhi (WT) or an S. Typhi strain expressing GtgE (::gtgE). Cells were lysed at the indicated time points to measure CFUs. (B) THP-1 
cells were transduced with lentivirus to silence the indicated Rab, infected with wild-type S. Typhi, and lysed at the indicated time points to measure CFUs. (C) Human 
macrophages derived from WT or HPS4−/− hiPSCs were infected with either wild-type S. Typhi (WT) or an S. Typhi strain expressing GtgE (::gtgE), lysed at the indicated time 
points for counting of intracellular CFUs. (D) Human macrophages derived from WT or HPS4−/− hiPSCs were infected with wild-type S. Typhi (WT) and lysed at the indicated 
time points to measure CFUs. (E) Human macrophages derived from WT or HPS4−/− hiPSCs were plated on glass coverslips, then infected with S. Typhi glmS∷Cm::mCherry 
or S. Typhi::gtgE glmS∷Cm::mCherry, and fixed at 1.5 and 24 hours p.i. Differentiated macrophages were identified by CD68 staining, and bacteria in CD68+ cells were 
counted. The whole populations are reported, and the infected versus total number of cells are indicated. Bars represent the mean and SD of the population. (F) Human 
macrophages derived from WT or HPS4−/− hiPSCs were infected with S. Typhi glmS∷Cm::mCherry or S. Typhi::gtgE glmS∷Cm::mCherry, fixed at 24 hours p.i., and analyzed 
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redundant effectors with different activities to target the Rab32/
BLOC-3-dependent pathway. In conclusion, here, we reveal that Rab32 
and BLOC-3 control a novel antimicrobial activity against a variety 
of infectious pathogens and demonstrate that S. Typhi uses its SPI-1 
type III secretion system to counteract this pathway and survive in 
human macrophages.
MATERIALS AND METHODS
Bacterial strains and plasmids
The wild-type S Typhi strain ISP2825 has been previously described 
(17). All the S. Typhi deletion strains were constructed by standard 
recombinant DNA and allelic exchange procedures as previously 
described (24) and are listed in table S1. All the plasmids used in 
this study were constructed using standard recombinant DNA 
techniques and are listed in table S2. S. Typhi glmS∷Cm::mCherry 
and S. Typhi::gtgE glmS::Cm::mCherry that constitutively express 
mCherry from a single chromosomal copy at the attTn7 site were 
generated by P22 transduction using phages obtained from the 
S. Typhimurium SL1344 glmS::Cm::mCherry [a gift from L. Knodler; 
(25)]. HPS4−/− (strain B6.C3-Pde6brd1 Hps4le/J) was purchased from 
the Jackson Laboratory.
Cell culture
THP-1 cells were maintained in RPMI 1640 medium (Invitrogen), 
10% fetal bovine serum (FBS; Invitrogen), 2 mM glutamine (Invitrogen), 
1 mM sodium pyruvate (Invitrogen), and 10 mM Hepes (Invitrogen). 
The cells were maintained at a concentration between 0.1 and 1 mil-
lion cells/ml. THP-1 differentiation was induced by adding 100 nM 
phorbol 12-myristate 13-acetate (PMA) for 48 hours before infec-
tion. For intracellular growth experiments, THP-1 differentiated 
cells were treated with human interferon- (IFN-) (150 ng/ml) 
24 hours before infection. Human embryonic kidney 293T cells 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
high glucose, 2 mM Glutamax (Invitrogen), and 10% FBS.
Blood was collected from healthy human volunteers, according 
to procedures approved by the Life Science and Medicine College 
Ethics Review Board of the University of Aberdeen (CERB/2016/ 
11/1299). Peripheral blood monocyte–derived macrophages were 
prepared as described in (26) with some modifications. Briefly, 
13 ml of blood was collected from each donor, diluted to 35 ml of 
Hanks’ balanced salt solution (HBSS; Invitrogen), and then loaded 
onto 15 ml of Lymphoprep (Stem Cell Technology) for the separa-
tion of the peripheral blood mononuclear cells. Isolated peripheral 
blood mononuclear cells were resuspended in DMEM containing 
A B
C D
S. aureus in WT
S. aureus in HPS4












Fig. 5. S. Typhi counteracts the Rab32/BLOC-3–dependent pathway through the SPI-1 type III secretion system. (A) Human macrophages derived from WT or 
HPS4−/− hiPSCs were infected with S. aureus and lysed at the indicated time points to measure intracellular CFUs. (B) Human macrophages derived from WT hiPSCs were 
infected with wild-type S. Typhi (WT) or E. coli O157 and lysed at the indicated time points to measure intracellular CFUs. (C) Human macrophages derived from WT or 
HPS4−/− hiPSCs were infected with either wild-type S. Typhi (WT) or S. Typhi ∆invA (∆invA). Cells were lysed at the indicated time points to measure intracellular CFUs. 
(D) Human macrophages derived from WT or HPS4−/− hiPSCs were infected with either wild-type S. Typhi (WT) or E. coli O157. Cells were lysed at the indicated time points to 
measure intracellular CFUs. Results in (B), (C), and (D) are reported as percentage of CFUs measured at the first time point (1.5 hours p.i.). Values are means ± SEM of at 









Baldassarre et al., Sci. Adv. 2021; 7 : eabb1795     15 January 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
6 of 8
10% autologous human serum (freshly prepared from the same do-
nor) and seeded on coverslips or tissue-treated plastic. Cells were 
plated at 5 ×105 per well in 24-well plates. After 24 hours, the non-
adherent cells were removed, fresh medium was added, and the cells 
were left for 7 to 9 days to differentiate.
Undifferentiated human-induced pluripotent stem cells line 
(KOLF2-C1) was maintained on a monolayer of mitotically in-
activated mouse embryonic feeder cells in advanced DMEM/F12 
medium, supplemented with 20% knockout replacement serum 
(Invitrogen), 2 mM l-glutamine, 0.055 mM -mercaptoethanol 
(Sigma-Aldrich), and recombinant human fibroblast growth factor 
2 (FGF2) (8 ng/ml; R&D Systems), as described previously (18). These 
cells were differentiated into macrophages as described in a previously 
published method (18).
C. albicans infection in wild-type or HPS4−/− mice
C. albicans (strain SC5314) was serially grown overnight at 30°C 
with shaking. Yeast cells were washed in phosphate-buffered saline 
(PBS; Sigma-Aldrich), counted, and injected intravenously via the 
lateral tail vein. Animals were infected with 2 × 105 CFUs. For anal-
ysis of fungal burdens in the kidneys, animals were euthanized 
72 hours p.i. Kidneys were weighed, homogenized in PBS, and seri-
ally diluted before plating on to YPD (yeast extract, peptone, and 
dextrose) agar supplemented with penicillin/streptomycin (Invitrogen). 
Colonies were counted after incubation at 37°C for 24 to 48 hours.
CRISPR-Cas9 targeting of HPS4
Isogenic intermediate targeting vectors for HPS4 were generated 
using isogenic and haplotype-specific DNA by polymerase chain 
reaction (PCR) amplification of KOLF2-C1 genomic DNA (gDNA). 
First, a PCR fragment including homology arms and the critical 
exon of HPS4 was amplified from KOLF2-C1 gDNA using the fol-
lowing primers: f5F gccagtgaattcgatatacctgccttcttgaactgttttg and 
f3R tacgccaagcttgatttaaattgtgctctgtgtgttcctc. The first 15 nucleotides 
(nt) of each primer (underlined) served to mediate fusion with the 
intermediate targeting vector backbone, puc19_RV, using an In- 
Fusion HD Cloning Plus kit (Takara Bio). The HSP4 amplicon was 
purified, and 75 ng was incubated with 50 ng of Eco RV–digested 
puc19_RV vector for 15 min at 50°C and transformed into Stellar 
competent cells (Takara Bio). Positive clones were verified by Sanger 
sequencing. To replace the critical exon with the gateway R1-pheS/
zeo-R2 cassette, sequence-verified clones were electroporated with 
the pBABgbaA plasmid (27). This was then maintained in tetracy-
cline (5 g/ml) at 30°C. Early log-phase cultures were induced to 
express the red operon following addition of 0.1% arabinose and 
incubation for 40 min at 37°C. From these cultures, electrocompe-
tent cells were prepared as previously described (25). The R1-pheS/
zeo-R2 cassette was amplified using the following primers: U5 ttagt-
ggtgtcagcagttctgagtatagagaggtagaatagtcccaagccaaggcgcataacgatac-
cac and D3 agttgtgcagcaagggaatggggctggaagaaaggggtctggagttactc-
ccgcctactgcgactataga. Underlined sequences in each of these 
primers denote 50 nt of homology toward a region 5′ (U5) or 3′ 
(D3) of the critical exon. This amplicon was purified, and 300 ng 
was electroporated into the recombination ready verified clones 
from the first step before selection in carbenicillin (50 g/ml) and 
zeocin (10 g/ml). Positive clones were verified by Sanger sequenc-
ing. To generate the donor plasmid for precise gene targeting via 
homology- directed repair, the intermediate targeting vectors were 
turned into donor plasmids via a Gateway exchange reaction. LR 
Clonase II Plus enzyme mix (Invitrogen) was used to perform a 
two-way reaction exchanging only the R1-pheS/zeo-R2 cassette 
with the pL1-EF1Puro-L2 cassette as previously described (27). 
The latter had been generated by cloning synthetic DNA fragments 
of the EF1 promoter and puromycin resistance cassette into a pL1/
L2 vector (27).
As part of the primer design process, two separate guide RNAs 
(gRNAs) targeting within the same critical exon were selected. The 
gRNAs were identified using the Wellcome Sanger Institute Genome 
Editing CRISPR tool (28) and were selected on the basis of their off- 
target scores to minimize potential off-target damage. gRNAs were 
suitably positioned to ensure DNA cleavage within the exonic region, 
excluding any sequence within the homology arms of the targeting 
vector. Plasmids carrying single gRNA sequences were generated 
by cloning forward and reverse strand oligos into the Bsa I site of 
either U6_Bsa I_gRNA or p1260_T7_Bsa I_gRNA vectors (provided 
by S. Gerety). The CRISPR sequences are as follows [protospacer 
adjacent motif (PAM) sequence]: left CRISPR (CCA), GCGAGAAT-
GTGAGGGCGAGCG; and right CRISPR (CCT), TCAGCAA-
CAACAGGGGCTCC (WGE IDs: 1181940311 and 1181940319, 
respectively).
To deliver plasmids expressing gRNA, donor templates, and Cas9, 
2 × 106 KOLF2-C1 cells were nucleofected (AMAXA nucleofector 
2B) with 2 g of donor plasmid, 4 g of hCas9 D10A (Addgene, 
plasmid #41816) (29), and 3 g of gRNA plasmid DNA. Following 
nucleofection, cells were selected for up to 11 days with 0.25 g ml−1 
puromycin. Individual colonies were picked into 96-well plates, ex-
panded, and genotyped. Positive insertion of the cassette into the 
correct locus was confirmed by PCR using cassette-specific primers 
ER (gcgatctctgggttctacgttagtg) and PNFLR (catgtctggatccggggg-
taccgcgtcgag). To determine the presence of deleterious inser-
tions or deletions (indels) around the CRISPR target site of the 
opposite allele, a PCR amplicon was generated using the primers PR 
(actagttctaacagctggtggatac) and PF (ttttgcagactgacaactattccag), pu-
rified, and Sanger-sequenced using SR1 (cttctggacaggcctccttg) and 
SF1 (atatttgccgaaccagccca). To minimize the potential for off-target 
effects, two independently derived clones, B09 and C08, with specific 
deletions of 47 and 29 base pairs, respectively, were isolated and 
used in this study.
Intracellular growth experiments
Overnight cultures of the different S. Typhi strains or S. aureus 
[strain SH1000 (30)] were diluted 1/20 in LB broth containing 
0.3 M NaCl and grown for 2 hours and 45 min at 37°C. Cells were 
infected with the different strains of S. Typhi in HBSS at the desired 
multiplicity of infections. One-hour p.i. cells were washed three 
times with HBSS and incubated in growth medium supplemented 
with gentamicin (100 g/ml) for 30 min to kill extracellular bacte-
ria. Cells were then washed with HBSS, and fresh DMEM contain-
ing gentamicin (5 g/ml) was added to avoid cycles of reinfection. 
At the indicated time points, the cells were washed twice in PBS, 
and the intracellular bacteria recovered lysing the cells in 0.1% sodi-
um deoxycholate (S. enterica) or 0.1% Triton X-100 (Sigma-Aldrich) 
(S. aureus) in PBS were counted by plating serial dilutions on 
LB-agar plates.
Western blot
PMA-differentiated THP-1 cells were infected as described above 
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2.5 hours p.i. Western blot analysis was performed using the Odyssey 
Infrared Imaging System (LI-COR Biosciences). The following 
antibodies were used for Western blot analysis: rabbit polyclonal 
anti-Rab32 (GeneTex; 1:1000 dilution) and donkey anti-rabbit IR 
Dye 800 (LI-COR Biosciences; 1:10,000 dilution).
Rab32 and Rab29 knockdown in THP-1
THP-1 cells were transduced with lentivirus expressing short hair-
pin RNA targeting Rab29 (TRCN0000299449, TRCN0000303685, 
TRCN0000381042, and TRCN0000303621, Sigma-Aldrich) or 
Rab32 (TRCN0000047746, Sigma-Aldrich). Twenty-four hours after 
transduction, cells were treated with puromycin (5 g/ml) to kill the 
nontransduced cells and kept in culture for not more than 2 weeks. 
Seventy-two hours before the infection, the cells were treated with 
100 nM PMA for 48 hours to induce differentiation. Twenty-four 
hours before the infection, the PMA was removed, and the cells 
were stimulated with human IFN- (100 ng/ml) and then finally 
infected with S. Typhi as described above.
Immunofluorescence
Bone marrow–derived mouse macrophages, human monocyte- 
derived macrophages, and wild-type or HPS4-deficient iPSDM 
were plated on glass coverslips (#1, Thermo Fisher Scientific) in-
fected with different S. Typhi strains or with S. aureus [strain 
SH1000 (30)] and fixed at the indicated times p.i. with 4% parafor-
maldehyde (PFA) for 10 min. Cells were then permeabilized for 
20 min by incubating in 0.02% saponin (Sigma-Aldrich), 0.2% BSA 
(Sigma-Aldrich), and 50 mM NH4Cl (Sigma-Aldrich) in PBS and 
incubated for 1 hour with monoclonal mouse anti-CD68 (KP1, 
Invitrogen; 1:200 dilution). Alternatively, cells were permeabilized 
for 20 min by incubating in 0.2% Triton X-100 (Sigma-Aldrich), 
0.2% BSA (Sigma-Aldrich), and 50 mM NH4Cl (Sigma-Aldrich) in 
PBS and incubated for 1 hour with a rabbit polyclonal anti-Rab32 
(GeneTex; 1:200 dilution). Cells were then stained using the appro-
priate Alexa Fluor 488– or Alexa Fluor 555–conjugated secondary 
antibodies (Invitrogen). Images were acquired using either a Nikon 
(Eclypse Ti2) equipped with a CFI (chromatic aberration free infinity) 
Plan Apochromat 100× objective and a Prime 95B 25-mm comple-
mentary metal oxide semiconductor (CMOS) camera (Photomet-
rics) or a PerkinElmer Spinning disk confocal equipped with an 
ORCA Flash 4.0 CMOS camera (Hamamatsu). Images were ana-
lyzed using the respective software (Nikon Elements or Volocity).
Live-cell fluorescence microscopy
Live-cell imaging experiments were performed at 37°C in a 
temperature-controlled chamber. Differentiated THP-1 cells plated 
on glass-bottom four-well chambers (1 × 105 cells) were infected 
with S. Typhi glmS∷Cm::mCherry at a multiplicity of infection of 
10. Five hours p.i., cells were stained with 1 M LysoSensor Green 
DND-189 (Thermo Fisher Scientific) for 10 min, washed three 
times with PBS, and imaged using a Nikon fluorescence microscope 
(Eclypse Ti2) equipped with a CFI Plan Apochromat 100× objective 
and a Prime 95B 25-mm CMOS camera (Photometrics).
To quantify the intensity of fluorescence of LysoSensor Green 
DND-189 in the SCV, a macro was developed for the ImageJ soft-
ware. Briefly, the S. Typhi glmS∷Cm::mCherry images were used to 
select the area of individual SCV and that selection was then used in 
the corresponding LysoSensor Green DND-189 image. The fluores-
cence value obtained for each SCV in both Rab32 knockdown and 
control cells was normalized on the basis of the maximal intensity 
value of control cells.
The level of cell fluorescence was quantified using ImageJ soft-
ware, and the level of corrected total cell fluorescence (CTCF) was 
calculated as follows: CTCF = Integrated Density – (area of selected 
cell × mean fluorescence of background readings). The values ob-
tained were normalized on the basis of the maximal intensity value 
of control cells.
Flow cytometry
hiPSC-derived macrophages wild type or HPS4 deficient were plated 
on non–tissue culture–treated six-well plates (Thermo Fisher 
Scientific) and infected with S. Typhi glmS::Cm::mCherry or S. Typhi:: 
gtgE glmS::Cm::mCherry. At the indicated time p.i., the cells were 
detached using 500 l of Versene (Invitrogen) and mixed with an 
equal volume of 4% PFA for 5 min. Fixed cells were then centri-
fuged and resuspended in 4% PFA for 5 min. The cells were then 
transferred in flow cytometry tubes, permeabilized for 15 min in 
PMZ-S (50 mM NH4Cl, 0.5 % bovine serum albumin, 0.05% saponin), 
and then incubated for 1 hour with anti-CD68 (1:200) and then with 
anti-mouse Alexa Fluor 488. The samples were analyzed by flow cyto-
metry (Fortessa, BD Biosciences) and FlowJo software.
Statistical analysis
CFU data in macrophages are presented as mean ± SEM. Differences 
between two groups were analyzed using the appropriate paired or 
unpaired Student’s t test. For C. albicans CFUs (Fig. 1C), the indi-
cated P values were determined by one-way analysis of variance 
(ANOVA) test with Dunnett’s posttest. P values of 0.05 or less were 
considered to be statistically significant. Excel (Microsoft) and 
GraphPad Prism7 (GraphPad Software Inc.) were used to perform 
all statistical analyses.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/3/eabb1795/DC1
View/request a protocol for this paper from Bio-protocol.
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